劑泰醫(yī)藥
賴才達(dá),劑泰醫(yī)藥聯(lián)合創(chuàng)始人兼首席執(zhí)行官。作為人工智能驅(qū)動(dòng)藥物研發(fā)的先鋒,其將藥物制劑、遞送技術(shù)和機(jī)器學(xué)習(xí)相結(jié)合,為劑泰醫(yī)藥技術(shù)平臺(tái)奠定了基礎(chǔ)。同時(shí),運(yùn)用多年創(chuàng)業(yè)經(jīng)驗(yàn)和數(shù)字化策略,帶領(lǐng)劑泰醫(yī)藥快速發(fā)展。
賴才達(dá)獲諾華制藥與MIT制造研究中心的博士學(xué)位,主要研究動(dòng)態(tài)建模、工藝優(yōu)化及藥物結(jié)晶。讀博期間,其創(chuàng)辦了凈水科技新創(chuàng)AquaFresco,成功研發(fā)出一項(xiàng)創(chuàng)新污水循環(huán)技術(shù)并使其商業(yè)化。另外,賴博士曾在麥肯錫擔(dān)任策略顧問(wèn),協(xié)助知名藥企制定數(shù)字化策略。
?
Chris is the co-founder and CEO at METiS. He is a pioneer in AI drug development. He integrated formulation, delivery technologies and machine learning to build the foundation of METiS’ platform. He also brought in years of entrepreneurship experience and digital strategy to guide the rapid growth of METiS.?
Chris received his PhD at the Novartis-MIT Center of Continuous Manufacturing. His research is primarily on process dynamic modeling, optimization and drug crystallization. During his tenure at MIT, he co-founded AquaFresco, an AIoT water-tech startup. He successfully developed an innovative wastewater recycling technology and enabled its commercialization. Chris also served as an consultant at McKinsey & Company’s Digital Practice, where he helped shape the digital strategy for many top insurance and pharmaceutical companies.